



Research Project for the Promotion of Innovative Drug Development for Emerging and Re-emerging Infectious Diseases

July 7, 2022

GenAhead Bio, Inc. is pleased to announce that our proposal has been accepted by the National Agency for Medical Research and Development (AMED) on June 17, 2022. We are pleased to announce that our proposal has been accepted by the Japan Agency for Medical Research and Development (AMED) on June 17, 2022.

Title: Study on prevention and therapeutics against viral infection using a novel nucleic acid delivery system “antibody-nucleic acid technology”, which has been applied in clinical trial.

Research and Development Representative: Yoshitaka Shirasago, Ph.D.

Research and Development Period: July 19, 2022 to March 31, 2023

https://www.amed.go.jp/koubo/11/02/1102C_00045.html

GenAhead Bio. Inc is a biopharmaceutical company with proprietary nucleic acid delivery and genome editing technologies based on a wealth of experience. The genome-editing technology is applied to the treatment of intractable diseases. In addition, our genome-editing technology is used in the drug discovery research of pharmaceutical companies and bio-venture companies by producing disease model cells at a high rate through genetic transformation of normal cells. We are committed to the innovative healthcare business, and to the creation of a new innovation hub and are located in the Shonan Health Innovation Park, which is a center for innovative healthcare businesses and new innovations.

GenAhead Bio. Inc: <https://en.genaheadbio.co.jp/>

Shonan Health Innovation Park: <https://www.shonan-health-innovation-park.com/en>

For inquiries, please contact: info@genaheadbio.com